While GLP-1 suppresses glucagon secretion at euglycemia, but not during hypoglycemia [18], GIP stimulates glucagon secretion at euglycemia, but not during hyperglycemia [19], being one of the reasons behind the apathy for GIP-based therapies for T2D. This evidence concerns the gene GCG and Hypoglycemia.